唑来膦酸对骨质疏松症患者骨痛评分及骨代谢指标的影响研究

Effect of Zoledronic Acid Injection on Bone Pain Score and Bone Metabolism Index in Patients with Osteoporosis

目的:研究唑来膦酸在骨质疏松治疗过程中所发挥的作用,并探讨其对骨代谢指标的影响情况。方法:2017年1月至2019年3月在我院收治的诊断为原发性骨质疏松症的160例患者,随机分成治疗组(80例)和对照组(80例)。对照组患者每日口服钙尔奇D片,疗程12个月,治疗组患者在此基础上静脉注射唑来膦酸(择泰)。用重复测量资料方差分析比较两组患者治疗前及治疗一年后的疼痛评分,相关部位骨密度及骨代谢相关指标。结果:两组患者的骨痛评分及骨密度各项指标、其它骨代谢指标差异均有统计学意义(P均<0.001),两组患者治疗前后差异均有统计学意义(P均<0.001),且不同组别与时间存在交互作用(P均<0.001)、两组治疗前后的差别不同,且治疗组变化幅度更大(P均<0.001)。两组患者的血钙(Ca)、血磷(P)、BGP水平差异无统计学意义,治疗前后差异也无统计学意义,且不存在交互作用;两组患者的BALP差异有统计学意义(P均<0.001),患者治疗前后,BALP水平差异均有统计学意义(P均<0.001),且不同组别与时间存在交互作用(P均<0.001)、两组治疗前后差别不同,且治疗组变化幅度更大(P均<0.001)。对照组发生率为7.50%,治疗组发生率为8.75%,两组不良反应发生率差异无统计学意义。结论:唑来膦酸能够有效改善骨痛和骨代谢相关指标,降低骨吸收,提高骨密度,不良反应少,患者依从性好。

Objective:To study the role of zoledronic acid in the treatment of osteoporosis and to explore its effect on bone metabolism.Methods:One hundred and sixty patients diagnosed as primary osteoporosis in our hospital from January 2017 to March 2019 were randomly divided into treatment group(80 cases)and control group(80 cases).Patients in the control group were giving oral Calcium D tablets daily for 12 months.Patients in the treatment group were given intravenous zoledronic acid(Zometa).ANOVA with repeated measurement data was used to compare the pain scores,bone mineral density and bone metabolism related indexes of the two groups of patients before and one year after treatment.Results:The differences in bone pain scores,bone mineral density,and other bone metabolism indexes between the two groups were statistically significant(P<0.001),and the differences before and after treatment were statistically significant(P<0.001).There is an interaction effect between the groups and time(P<0.001).The differences between the two groups before and after treatment were different,and the treatment group has a larger change(P<0.001).There was no statistically significant difference in blood calcium(Ca),blood phosphorus(P),and BGP levels between the two groups of patients,nor was the difference between before and after treatment,and there was no interaction;the difference in BALP between the two groups was statistically significant(P<0.001),the differences in BALP levels before and after treatment were statistically significant(P<0.001),and there was an interaction between different groups and time(P<0.001),and the differences between the two groups before and after treatment were different.The group changed more significantly(P<0.001).The incidence of the control group was 7.50%,and the incidence of the treatment group was 8.75%.There was no significant difference in the incidence of adverse reactions between the two groups.Conclusion:Zoledronic acid can effectively improve bone pain and bone metabolism related indicators,reduce bone resorption,increase bone density,less adverse reactions,and better patient compliance.